Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients

Modern Rheumatology

Volumn 21, Issue 4, 2011, Pages 375-380

  Ishaq, Muhammad ^a   Muhammad, Jibran Sualeh ^a   Hameed, Kamran ^b   Mirza, Ahmad Iqbal ^b  

^a JINNAH MEDICAL AND DENTAL COLLEGE   (Pakistan)

^b ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Efficacy; Low socioeconomic; Methotrexate and leflunomide; Rheumatoid arthritis; Toxicity

Indexed keywords

LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE;

ADULT; ALOPECIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL PAIN; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; JOINT STIFFNESS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RASH; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; NAUSEA; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 83255164819     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0405-4     Document Type: Article

References (23)

1. Fauc AS, Braunwald E, Kasper DL, Hauser SL. Harrison's principles of internal medicine. 2008;2275-76.
2. Farooqi AZ, Gibson T. Prevalence of major rheumatic disorders in the adult population of northern Pakistan. Br J Rheum. 1998;37:491-5.
3. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthr Rheum. 2000;43:22.
4. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr Rheum. 2008;59:762.
5. Felson DT, Anderson JJ, Meehan RF. Use of short-term efficacy/ toxicity trade-offs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthr Rheum. 1992;35:1117-25.
6. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992;19: 1885-94. (Pubitemid 23018519)
7. Kremer JM. Use of methotrexate in the treatment of rheumatoid arthritis. 2010 Feb. http://www.uptodate.com/patients/content/ topic.do?topicKey= RE9ECo2VBPsA2g. Cited on 20 May 2010.
8. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996;35:1270-3. (Pubitemid 26050790)
9. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T lymphocytes from healthy humans. J Biol Chem. 1998;273: 21682-91. (Pubitemid 28405342)
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315-24. (Pubitemid 18091653)
11. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med. 1994;330:1368-75. (Pubitemid 24136062)
12. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol. 1998;25:408-16. (Pubitemid 28109338)
13. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995;270:29682-9.
14. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthr Rheum. 1992;35:729-35.
15. Weber W, Harnisch L. Use of a population approach to the development of leflunomide: a new disease-modifying drug in the treatment of rheumatoid arthritis. In: Aarons L, Balant LP, Danhof M, et al., editors. European cooperation in the field of scientific and technical research. Brussels: European Commission Directorate-General Science, Research and Development; 1997. p. 239-44.
16. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-50.
17. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833-41.
18. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998;1:36-43. (Pubitemid 28060115)
19. Van Ede A, Laan R, Rood M, et al. Effect of folic and folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double-blind, 48-week clinical trial. Arthr Rheum. 1999;42(Suppl):S380.
20. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39:655.
21. Dayer JM, Cutolo M. Is there a rationale to using leflunomide in early rheumatoid arthritis? Clin Exp Rheumatol. 2005;23:404.
22. Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract. 2003;57:115.
23. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; CD002047.